Servier achieves a development milestone for HDAC inhibitor S-78454


Servier and Pharmacyclics announced today that they have reached a development milestone for their histone deacetylase (HDAC) inhibitor, S-78454. Over the past two years Servier has engaged in several exploratory Phase I/II trials in solid tumors and hematologic malignancies. Servier is now focused on its Phase II programs to enable the registration pathway for S-78454.

“Five phase I and I/II trials are ongoing in Europe in lymphomas and solid tumors. The first results are very encouraging in terms of clinical activity and safety profile and we plan to start soon new combination trials”, said Stéphane Depil MD, PhD, director of Oncology Research and Development Unit at Servier. 

“Servier is delighted to work with Pharmacyclics under this partnership,” said Emmanuel Canet MD, PhD, Servier's President, Research and Development, “the molecule S-78454 has performed well in a variety of early stage trials and exceeds our expectations. We plan to further expand the clinical development of S-78454.”